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Background: The current study was designed to test if an objective measure of both attention and movement
would differentiate children with Oral Language Disorders (OLD) from those with comorbid Attention Deficit/
Hyperactivity Disorder (ADHD) and if stimulant medication improved performance when both disorders were
present.
Methods: The sample consisted of thirty-three children with an identified oral language disorder (of which 22 had
comorbid ADHD) ages 6 to 13 who were enrolled in a yearlong intensive learning intervention program. Those on
a stimulant medication were tested at baseline and again a year later on and off medication.
Results: Objective measures that included an infrared motion analysis system which tracked and recorded subtle
movements discriminated children with OLD from those with a comorbid ADHD disorder whereas classic attention
measures did not. There were better attention scores and fewer movements in children while on-medication.
Conclusions: Use of an objective measurement that includes movement detection improves objective diagnostic
differential for OLD and ADHD and provides quantifiable changes in performance related to medication for both
OLD and ADHD.
Keywords: Oral language disorders, ADHD, Inattention, Hyperactivity/Impulsivity, Language, Cognitive processing,
Continuous performance testing, Movement detectionBackground
A language impairment (LI) or language disorder is a
deficit or delay in receptive language (the understanding
of spoken language by others) and/or expressive lan-
guage (the sharing of thoughts, ideas, and feelings). An
assortment of terms have been used to refer to this LI
condition, including specific language impairment (SLI),
developmental language disorder, expressive language
disorder, developmental dysphasia or aphasia [1], and
various subtypes of communication disorders [2].
Attention-Deficit/Hyperactivity Disorder (ADHD) is one
of the most common comorbid diagnoses for children
with an expressive language disorder or mixed receptive-
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unless otherwise stated.as oral language difficulties – OLD) [3,4]. Conversely,
studies have indicated that children with ADHD are at
risk for learning problems or learning disorders [5,6]. An
estimated 50% of children with ADHD have a comorbid
oral language deficit [4,7], while 20 to 60% of children
with ADHD have one or more learning disabilities or
language problems [8]. Children with co-occurring OLD
and ADHD are expected to experience more academic
difficulties [9] and a wide variety of performance issues
in language, coordination, attention, and perception, and
as well have more difficulties with social skills and emo-
tional well-being [10].
Due to inattention and impulsivity in children with
OLD, they are frequently mistaken for symptoms of
ADHD. Studies have found that children with deficits in
pragmatic language displayed excessive talking, provided
insufficient information upon responding, had poor turn-
taking skills, and demonstrated difficulty maintainingl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by McInnes and colleagues [13], lower listening compre-
hension and working memory performance was evident in
children with language impairment. The diagnostic
dilemma becomes that these inattention symptoms and
behavior control difficulties in children with OLD can ap-
pear quite similar to inattention and hyperactivity symp-
toms seen in children with ADHD and consequently,
some with OLD only may be prescribed medication with-
out established efficacy. Or, the language disorder may be
missed all together and the focus becomes ADHD without
addressing the language disorder. And then there are
those with OLD and comorbid ADHD where an accurate
language disorder diagnosis fails to identify the concomi-
tant ADHD where the addition of a medication interven-
tion may prove beneficial.
Due to overlapping symptoms and similar behavior dis-
turbance, differential diagnostic accuracy can be challen-
ging. It is important to establish an accurate diagnostic
differential to guide appropriate treatment intervention
(e.g., whether one should be tried on a stimulant medica-
tion). There is a need for an objective measure to improve
differential diagnostic acumen for co-occurring OLD and
ADHD as a precursor to medication intervention. Medica-
tion is one of the most common approaches to treat
ADHD symptoms in children and has been successfully as-
sociated with improvements in functioning [14]. A myriad
of studies have identified stimulant medication to improve
executive functioning in adults and children with ADHD,
while other studies have shown stimulant medication to
improve behavioral issues, such as self-regulation related to
movement [14,15]. Little research exists for those with a
well-defined diagnosis of concomitant OLD/ADHD.
Fortunately, an objective measure of attention such as
the Continuous Performance Test (CPT) has proven an ef-
fective, popular, and efficient means of objectively assessing
attention [16], especially in individuals with suspected
ADHD [17]. The CPT minimizes any aspect of potential
bias from self, parent, teacher, or clinician reporting of
symptoms. The mechanism by which a CPT detects
ADHD-like symptoms is by identifying the test-takers’ re-
sponse patterns. Inattentive and hyperactive/impulsive
symptoms are two separate variables, tabulated by the
amount of missed responses to “target” stimuli (omissions)
and responses to “non-target” stimuli (commissions)
compared to a normative sample. Errors of omission are
assumed to reflect symptoms of inattention and commis-
sions hyperactivity/impulsivity [18-20]. Most studies exam-
ining the psychometrics of various CPTs agree that it is a
reliable and valid clinical tool to use as part of a more
comprehensive assessment of ADHD [21] but not OLD.
However, the CPT alone has not been established as a tool
for “diagnosing” ADHD. There is insufficient data in the
extant literature to demonstrate the CPT’s ability todifferentiate OLD from OLD with ADHD. One explan-
ation for that is the traditional CPT utilizes only measures
of attention which is a common deficit found for both dis-
orders and does not include movement variables [22-24].
The Quotient® ADHD System is a classic objective
measure of various CPT go, no-go, attention variables
(e.g., accuracy, omissions, commissions, variability), but
unlike other CPTs, it is the only one combined with infra-
red motion detectors (e.g., number of movements, immo-
bility duration, displacement, area) [Quotient®, BioBeha
vioral Diagnostics, Inc., 2010; purchased by Pearson, Inc.,
2013] [25]. Previous work with motion detectors has dem-
onstrated that children with ADHD in a CPT task spent
66% less time immobile than normal children, moved
their head 3.4 times as far, covered a 3.8 times greater
area, and had a movement pattern that was more complex
[26]. Teicher’s research group [24] has recently suggested
that the inability to inhibit subtle movements detected by
the Quotient® for individuals with ADHD may represent
deficits in functional activity of the cerebellar vermis,
whereas the inhibition of attention measures may reflect
deficits in functional capacity of frontostriatal areas and
that both areas respond positively to stimulant
medication.
The study reported here tested both attention and
movement measurements in children with an OLD and
those with both disorders (OLD/ADHD). Additionally,
since research supports that stimulant medication
improves attention and body control, we assessed the
effects of being on- versus off- medication differences
for OLD/ADHD at baseline and following focused train-
ing for language impairment again a year later where
individuals had been on stimulant medication at both
time points. An initial dissertation study at baseline had
hypothesized that both attention and movement scores
would differentiate OLD from OLD/ADHD but only
movement was found to discriminate the two (30).
Based on that finding, for the longitudinal follow-up
study a year later, it was hypothesized that only move-
ment measures would differentiate those with OLD from
a group with a comorbid OLD/ADHD diagnosis (31). It
was further hypothesized that the effects of stimulant
medication treatment would improve attention scores
for those with ADHD, while decreasing movement, and
that these effects could be seen at baseline and repli-
cated a year later.
Methods
Participants
Thirty-three participants were between the ages of 6 and
13 years (15 =male; 18 = female) from an original sample
of 67. The participants in the study attended a specially
designed early language intervention program at the
Shelton School [27], a large private school for children
Figure 1 Participant data collection flow chart.
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in the study, the participant had to have a primary diagno-
sis of Oral Language Disability (OLD) diagnosed by a team
of speech-language pathologists, licensed psychologists,
and educational diagnosticians at Shelton School and en-
rolled in the school’s specially designed early intervention
program. OLD children had: (a) low average (85 – 89) or
below average (<85) verbal IQ, (b) below average (<85)
auditory processing, processing speed, visual perceptual
ability, reading comprehension, spelling, or handwriting,
and (c) average reading rate and accuracy (85 – 115). In
addition, their receptive and expressive language perform-
ance was in the moderate to severe range of impairment or
below 85. Those participants with a comorbid ADHD
diagnosis had one of the four subtypes of Predominantly
Inattentive Type, Predominantly Hyperactive-Impulsive
Type, Combined Type, or ADHD Not Otherwise Specified.
Participants in the study were not excluded for taking a
stimulant ADHD medication, but were asked to be able to
be tested on and off their medication (i.e., parent and child
provided consent and assent). The choice to be on medica-
tion was based on parent and community physician deci-
sions for treatment. School and study personnel had no
control over that, rather we could only indicate if they were
on the medication or not. The school nurse knew what
medication they were taking, but not the doses. All testing
was done within the first two hours of the school day. One
on non-stimulant psychotropic medication was excluded.
Participants with a history of head injury (a period of un-
consciousness followed by lasting impairment) or a neuro-
logical disorder, such as a seizure disorder, were excluded
(Figure 1).
To determine if the child had ADHD, the parent and
the child separately were administered the Kiddie Sched-
ule for Affective Disorders and Schizophrenia in School
Age Children, Present and Lifetime (K-SADS-P/L) [28]
which uses the same diagnostic criteria as the DSM-IV-
TR. All items of ADHD syndrome were administered to
both the parent and the child. Specifically, to be diag-
nosed with ADHD, a participant had to receive ratings
of “three - definitely present” for six of the nine inatten-
tive symptoms (ADHD-IA), or six of the nine hyper-
active symptoms (ADHD-HI), or a minimum of six
inattentive and six hyperactive/impulsive symptoms
(ADHD-C) prior to the age of seven. Children were di-
agnosed with ADHD NOS if ratings did not meet full
symptom criteria (e.g., a minimum of 6 criterion symp-
toms rated as a “three”), but had prominent symptoms
of inattention and/or hyperactivity/impulsivity present
and causing impairment (e.g., a minimum of four symp-
toms but < 6 criterion symptoms rated as a “three”). Reli-
ability studies of the K-SADS-P/L report high inter-rater
reliability (range: 93% to 100%) and excellent test-retest
reliability [28].Measures
Quotient® ADHD System
The Quotient® is a computerized continuous perform-
ance test assessing a participant’s ability to pay attention
and ability to sit still [25]. It provides precise, reliable,
and reproducible information on symptom severity
under controlled conditions that replicate a classroom
environment. Participants wear a headband with an
attached motion reflector, which faces an infrared
motion analysis tracking system (located just above the
computer monitor). Movement greater than 0.04 mm
resolution is detected by the tracking system from the
motion reflector, and movement data is collected nearly
50 times per second throughout the 15-minute task [24].
Participants are asked to press the space bar each time
they see an eight-pointed star but to inhibit their re-
sponse to five-pointed stars. Each target appears on a
white computer screen for 200 milliseconds in different,
random spots on the screen at 2-second intervals. Vari-
ables collected include movement (number of position
changes), displacement (total distance moved), temporal
scaling (pattern of movement in time; lower values
Table 1 Demographic characteristics of the study’s
sample
Total sample OLD OLD/ADHD
(N = 33) (n = 13) (n = 20)
N (%) n (%) n (%)
Gender
Male 15 (46%) 7 (54%) 8 (40%)
Female 18 (54%) 6 (46%) 12 (60%)
Ethnicity
Caucasian 27 (77%) 11 (85%) 15 (75%)
Hispanic 3 (9%) 0 (0%) 2 (10%)
African
American 1 (3%) 0 (0%) 1 (5%)
Asian 1 (3%) 0 (0%) 1 (5%)
Other 3 (8%) 2 (15%) 1 (5%)
ADHD type
Inattentive 6 (18%) N/A 6 (30%)
Hyperactive-
Impulsive 1 (3%) N/A 1 (5%)
Combined 6 (18%) N/A 6 (30%)
NOS 7 (22%) N/A 7 (35%)
aMedication 20 (61%) 4 (31%) 16 (80%)
aParticipants prescribed stimulant medication duration of study period.
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sponses), omission errors (percentage of missed targets),
commission errors (percentage of inaccurate responses to
non-targets), latency (average amount of time to respond
correctly), and variability (variation in response time to
the correct target). We recently confirmed the factor load-
ings for ADHD using the Quotient® [29].
Design and procedure
This study was reviewed and approved by the Shelton
School Internal Review Board (IRB) and the University
of Texas Southwestern Medical Center IRB. Both the
child and parent gave informed verbal and written assent
and consent to participate in the study.
Baseline data Time 1 (T1) data were collected during
the Spring [30] and Time 2 (T2) data were collected
again during the following Spring after completing a
specially designed year-long oral language school inter-
vention [31]. All testing was conducted at the Shelton
School in a quiet, secluded testing area during the first
periods of school in the morning. Participants were
tested one at a time. During the 15 minute test, the
administrator stayed in the testing room to notate obser-
vations, without talking to the participant and to assure
that they remained on task. Participants off of their
medication were tested after arriving at school, and then
upon completion were taken to the school nurse for
medication administration and then onto class. Testing
was conducted on different days for those who partici-
pated in the either on or off of their medication condi-
tion (the counterbalanced order of testing was random).
That they had taken, or not taken their medication prior
to arriving to school, was verified by the study staff prior
to testing. Upon completion of the test, data were trans-
mitted and analyzed by BioBehavioral Diagnostics on a
central server. Data were then compared to a normative
group by age and gender and a report was produced
including statistical and graphical information about
attention and movement variables.
Data analysis
Demographic characteristics for the overall sample are
described using the sample mean and standard deviation
for continuous variables and the frequency and percent-
age for categorical variables. To test the Quotient®
ADHD attention and movement variables, the basic de-
sign was a two-group (OLD vs. OLD/ADHD), by Time
(T1 and T2) repeated measures Analysis of Variance
(ANOVA) design using SPSS Version 19. A secondary
analysis of medication (ON or OFF) by Time analysis
was conducted for an OLD/ADHD subgroup of 16 par-
ticipants taking stimulant medication at both time points
(the four OLD participants on medication were excluded
for the medication analyses).Results
Of the sixty-seven participants enrolled in the Shelton
School Language Intervention program, thirty-three met
criteria for the current study (see Consort Figure 1).
There were 18 females and 15 males, ranging in age
from 6 to 13 (M =9.4 years, SD = 2.1) who completed all
testing. All had an OLD diagnosis and 22 (62.9%) also
met criteria for a diagnosis of ADHD. A separate sec-
ondary analysis was performed on all participants who
were also taking a stimulant medication at both time
points on and off of medication (Table 1).
To assess if the OLD and OLD/ADHD groups were
equivalent in overall functioning and severity with regard
to language and cognitive functioning, independent-
samples t tests indicated no group differences with respect
to language functioning (Clinical Evaluation of Language
Fundamentals – CELF), verbal cognitive ability (Slosson
Intelligence Test-Revised), and nonverbal cognitive ability
(Wechsler Nonverbal Scale of Ability). Teacher reports on
the Behavioral Assessment System for Children (BASC)
were examined to determine if groups differed with re-
spect to internalizing symptoms (Internalizing Compos-
ite), externalizing symptoms (Externalizing Composite),
overall behavioral symptoms (Behavioral Symptoms Com-
posite) and adaptive behavior (Adaptability Composite).
No differences were found and hence, none of these mea-
sures were used as covariates for the analyses that follow.
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The means and standard deviations for the various Quo-
tient® movement variables are reported in Table 2. The
OLD/ADHD group had a significantly greater number
of movements at both Time 1 and Time 2 than the OLD
group F(1,29) = 8.54, p < .007, η2 = 0.23, a large effect
size. Effect size is a partial eta-squared (η2) where values
of .01, .06, and .14 represent small, medium, and large
effects sizes [32]. Likewise, children with OLD/ADHD
had significantly greater distance in their movements
(“displacement”) at both Time 1 and Time 2 than the
OLD group F(1,29) = 7.76, p < .01, η2 = 0.21) and greater
area represented in their movements at both Time 1 and
Time 2 than the OLD group F(1,29) = 10.64, p < .003,
η2 = 0.27. Finally, children with OLD/ADHD had a
higher frequency of movements (“temporal scaling”) at
both T1 and T2 than the OLD group F(1,29) = 8.30,
p < .01, η2 = 0.22, but the spatial complexity of the
movements did not differ between groups. There were
no interactions or effect of T1 versus T2. The test-
retest reliability for the movement measures was good
to excellent with all p values less than 0.001: immobility
(r = .75), movement (r = .82), displacement (r = .75); area
(r = .66); spatial complexity (r = .65) and temporal scal-
ing (r = .86).
A MANOVA at baseline to minimize possibility of Type
I error, found no significant group differences on the at-
tention variables so they are not reported, Wilk’s Λ =
0.915, F(4, 46) = 1.07, p = .38, [30], or again at T2 [32].
The attention scores were impaired compared to norms
(e.g., mean accuracy scores for OLD of 81% and 78% for
OLD/ADHD whereas normal performance would be in
the low to mid 90s [23]. Separate power analyses indicated
that much larger group sizes would be required (>200) for
differences at p < .05 and power of 80.Table 2 Two-way repeated measures analyses of variance to
groups
OLD (n =12) OLD/ADHD
M (SD) M (SD)
T1 T2 T1
Immobility duration 213.58(116.84) 222.25 (159.82) 115.11 (122
Movements 2032.67(1020.75) 2458.25 (2086.34) 4837.84 (27
Displacement 2.73 (1.58) 3.82 (4.22) 8.70 (6.15)
Area 66.17 (50.41) 107.67 (153.53) 265.37 (154
Spatial complexity 1.20 (.10) 1.20 (.13) 1.12 (.14)
Temporal scaling .60 (.24) .59 (.37) .98 (.42)
*Significant p-value alpha level of .01. η2 effect sizes of .01, 06, and .14 represent sm
Immobility Duration: Average amount of time, in seconds, spent sitting still (moving
Movements: Average number of position changes (movement greater than 1 mm),
Displacement: Total distance traveled (in meters) by the marker during a 5 min. per
Area: Size and shape, measured in cm2, of the space covered by the marker during
Spatial Complexity: Complexity of the movement path. (Values range from one to t
indicate more complex movement.
Temporal Scaling: Frequency of movement (scale from 0 to 1; 0 = no movement anA discriminant function analysis was conducted using
all of the baseline movement scores to predict OLD ver-
sus OLD/ADHD group membership. The Wilk’s
Lambda chi square was significant at 16.3 (df = 6), and
p = .01, with 82.8% of the groups correctly classified. The
Kappa was 0.66, p < .001. A separate sensitivity/specifi-
city analysis indicated 73.3% sensitivity and 92.9 specifi-
city, with a positive predictive value of 91.7%. The
findings provide strong support that body movements as
measured by the Quotient® during a CPT task can sig-
nificantly differentiate those children with OLD only
diagnoses from those with OLD and ADHD and are
stable indices whereas by contrast, there were no differ-
ences based on classic CPT attention measures.
Movement differences by medication condition: a
secondary analytic approach
To assess the effects of medication, a secondary set of ana-
lyses utilized a within subject two group (On Medication
versus Off Medication) repeated measures ANOVA based
on Time 1 and Time 2 (a year later) for a subgroup who
were on medication at both time periods. The means and
standard deviations for the various Quotient® ADHD Sys-
tem movement variables are reported in Table 3. All
movement measurements were significantly different
when on medications. There were no interactions or effect
of T1 versus T2. Children spent more time sitting still
(“immobility duration”) compared to their performance
off medication at both T1 and T2 F(1,15) = 20.54, p < .00,
η2 = .58, representing a large effect size. They had fewer
position changes (less “movement”) when tested on medi-
cation compared to their performance off medication at
both T1 and T2 F(1,15) = 26.10 p < .00, η2 = .64, and
shorter total distance of movements (“area”) when tested
off medication F(1,15) = 22.45 p < .00, η2 = .60. Childrenexamine Quotient® movement variables for diagnostic
(n = 19)
T2 Statistic Value p η2
.70) 118.32 (110.82) Group F(1,29) 5.49 .26
46.45) 4457.68 (2646.04) Group F(1,29) 8.54 .01* .23
8.11 (6.61) Group F(1,29) 7.76 .01* .21
.55) 266.11 (229.09) Group F(1,29) 10.64 .003* .27
1.11 (.14) Group F(1,29) 0.10 .09
.98 (.42) Group F(1,29) 8.30 .01* .22
all, medium, and large effects sizes respectively.
less than 1 mm) during a 5 min. period.
measured in total meters during a 5 min. period.
iod.
a 5 min. period.
wo). Lower values indicate more linear, back & forth movement; higher values
d 1 = constant movement).
Table 3 Two-way repeated measures analyses of variance to examine Quotient® movement variables for medication
condition
Off medication (n = 16) On medication (n =16)
M (SD) M (SD)
T1 T2 T1 T2 Statistic Value p η2
Immobility duration 123.38 (129.02) 106.81 (106.56) 195.56 (130.51) 244.50 (189.01) Group F(1,15) 20.54 .000* .58
Movements 4841.56 (3007.52) 4916.62 (2768.34) 2342.44 (1409.24) 2343.56 (1930.90) Group F(1,15) 26.10 .000* .64
Displacement 8.83 (6.76) 9.23 (7.06) 3.44 (2.64) 3.54 (3.57) Group F(1,15) 22.45 .000* .60
Area 250.25 (172.73) 300.13 (255.54) 87.25 (84.52) 91.06 (113.39) Group F(1,15) 31.08 .000* .67
Spatial complexity 1.14 (.15) 1.10 (.12) 1.19 (.14) 1.25 (.19) Group F(1,15) 17.54 .001* .54
Temporal scaling .99 (.44) 1.07 (.42) .67 (.30) .65 (.39) Group F(1,15) 24.49 .000* .62
*Significant p-value alpha level of .01. η2 effect sizes of .01, 06, and .14 represent small, medium, and large effects sizes respectively.
Immobility Duration: Average amount of time, in seconds, spent sitting still (moving less than 1 mm) during a 5 min. period.
Movements: Average number of position changes (movement greater than 1 mm), measured in total meters during a 5 min. period.
Displacement: Total distance traveled (in meters) by the marker during a 5 min. period.
Area: Size and shape, measured in cm2, of the space covered by the marker during a 5 min. period.
Spatial Complexity: Complexity of the movement path (values range from one to two). Lower values indicate more linear, back & forth movement; higher values
indicate more complex movement.
Temporal Scaling: Frequency of movement (scale from 0 to 1; 0 = no movement and 1 = constant movement).
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smaller) when tested on medication compared to their per-
formance off medication at both T1 and T2 F(1,15) = 31.08
p < .00, η2 = .67. They also had a higher “spatial complexity”
score (i.e., movements were qualitatively more complex)
when tested on medication compared to their performance
off medication at both T1 and T2 F(1,15) = 17.54, p < .00,
η2 = .54. Children tested on medication had significantly
less frequent movements (“temporal scaling”) at both
T1 and T2 compared to more frequent movements
when tested off medication F(1,15) = 24.49 p < .00,
η2 = .62. Using the Quotient® ADHD System to measure
movement, children tested on medication spent signi-
ficantly more time sitting still, had fewer position
changes, traveled less distance in their movements,
had smaller area of movement, had less frequentTable 4 Two-way repeated measures analyses of variance to
condition
Off medication (n = 16) On medicat
M (SD) M (SD)
T1 T2 T1
Accuracy 81.14 (13.81) 85.91 (12.09) 86.44 (12.40)
Omission errors 14.19 (14.49) 11.11 (15.11) 4.08 (5.88)
Commission errors 23.56 (16.27) 16.96 (13.33) 23.14 (19.74)
Variability 217.44 (81.27) 198.00 (88.15) 153.63 (76.77
Latency 598.37 (105.77) 584.63 (89.17) 545.44 (81.50
COV 35.50 (11.42) 32.25 (10.06) 27.13 (10.91)
*Significant p-value alpha level of .01. η2 effect sizes of .01, 06, and .14 represent sm
Accuracy: Percentage of correct responses to both target and non-target.
Omission Errors: Percentage of missed targets.
Commission Errors: Percentage of incorrect responses to non-target.
Latency: Mean time, in milliseconds, to respond to target.
Variability: Standard deviation of response time to target.
Coefficient of Variance (COV): A more stringent measure of response consistency: (1movements, and had more complex movements at both
T1 and T2.
Attention differences by medication condition
The means and standard deviations for the various
Quotient® ADHD System attention variables are re-
ported in Table 4. Children had better “accuracy” scores
at both time points while medicated F(1,15) = 8.14,
p < .01, η2 = .35. Likewise they had fewer “omissions”
(i.e., fewer missed targets) when tested on medication
compared to their performance off medication F(1,15) =
9.90, p < .01, η2 = .40, but no differences for incorrect
responses to non-targets (“commissions”). “Variability”
(defined as the standard deviation of response time to tar-
get) was significantly lower on medication compared to
their performance off medication F(1,15) = 33.62, p < .00,examine Quotient® attention variables for medication
ion (n =16)
T2 Statistic Value p η2
89.83 (6.30) Group F(1,15) 8.14 .01* .35
3.89 (5.37) Group F(1,15) 9.90 .01* .40
16.46 (8.94) Group F(1,15) .06 .81
) 122.75 (55.26) Group F(1,15) 33.62 .00* .69
) 495.37 (80.31) Group F(1,15) 28.03 .00* .65
23.69 (7.49) Group F(1,15) 32.28 .00* .68
all, medium, and large effects sizes respectively.
00 x variability)/latency.
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faster when they were on medication compared to their
performance off medication F(1,15) = 28.03, p < .00,
η2 = .65. For Coefficient of Variance (COV) [a more strin-
gent measure of response consistency: (100 x variability)/
latency], response consistency was significantly greater
when children were tested on medication compared to
their performance off medication F(1,15) = 32.28, p < .00,
η2 = .68. These attention scores clearly indicate that stimu-
lant medication improves attention performance during a
fifteen minute continuance performance task with signifi-
cantly better accuracy, fewer omission errors, faster re-
sponse time, and less variability.
Attention state differences by medication condition
Additional measures calculated by the Quotient® ADHD
System are known as attention state variables. For ex-
ample, attention shifts and the number of shifts in atten-
tion state are defined as On Task (percent of time hit
many targets and few non-targets), Distracted (percent
of time hits some targets and some non-targets; accuracy
is better than chance), Impulsive (percent of time hits
many targets and some non-targets), Random Respond-
ing (hits most targets and non-targets; accuracy of
responding is as good as chance), Minimal Responding
(misses most targets and non-targets; accuracy is about
as good as chance), and Contrary (response accuracy is
significantly worse than chance). The analyses of these
variables indicate that the children spent more time
responding “on task” when they were tested on medica-
tion F(1,15) = 4.66, p < .05, η2 = .24, spent a lower per-
centage of time in a “distracted” attention state, and less
time in the “minimal responding” attention state profile
(i.e., children were less likely to make both omission and
commission errors) F(1,15) = 4.92, p < .04, η2 = .25.
Discussion and conclusions
This study found that children with oral language disorder
(OLD) and comorbid ADHD performed significantly dif-
ferent from those with an OLD-only diagnosis based on
subtle, measureable movement scores but not classic CPT
attention variables. Importantly, movement measures such
as position changes, larger displacement of head move-
ments (i.e., total distance traveled per unit time), larger
area of movement, and more temporal scaling (i.e., fre-
quency of movement) as measured by the Quotient®
ADHD System do significantly differentiate the two
groups with good statistical group classification and sensi-
tivity and specificity. This suggests that relying on CPT-
like measures alone (without movement measurements)
would probably not meaningfully differentiate the two
groups. Unlike other CPTs that do not measure move-
ment, these additional movement variables are valuable
additions to tests to distinguish the overlap of core ADHDsymptoms in children with OLD and would assist diag-
nostic classification. These findings lend support to
Ohashi et al.’s [24] contention that the inability to inhibit
subtle movements detected by the Quotient® for individ-
uals with ADHD may represent deficits in functional ac-
tivity of the cerebellar vermis [33] that can uniquely
differentiate children with OLD/ADHD from those only
with OLD. Both groups appeared to equally show impair-
ment in measures of attention which likely reflect deficits
in functional capacity of frontostriatal areas [34,35]. The
Quotient® significantly improves the ability to accurately
differentiate OLD from OLD/ADHD children when com-
pared to traditional CPT attention measures only. Utiliz-
ing assessments that included objective, quantifiable
movement measures may improve the accuracy of the dif-
ferential diagnosis.
CPTs have proven to be a reliable and valid clinical tool
to include as part of a clinical assessment battery for
ADHD but not for differentiating ADHD from OLD and
learning disabilities in general, as both disorders have
similar difficulty with various attention variables
[18,20,21,36]. Unlike traditional CPTs, the Quotient® is a
CPT designed to measure additional core symptoms of
ADHD based on movement and attention shifts. In 2009,
Baker found five movement variables to discriminate chil-
dren with OLD from OLD/ADHD. The current study rep-
licates the findings and extends them to repeated
measures one year later supporting good test-retest reli-
ability [30]. Specifically, four of the six Quotient® move-
ment variables consistently discriminated children with
OLD from OLD/ADHD. It discriminated all six move-
ment measures when controlling for medication. Children
with OLD/ADHD did not differ from OLD children on
immobility duration (i.e., time spent sitting still) or spatial
complexity (i.e., complexity of movement path; lower
value indicating more linear or back and forth move-
ments). Despite questionable ADHD symptom overlap in
OLD and ADHD children due to the use of subjective as-
sessment protocols, this is the first study to investigate the
utility of the objective Quotient® for discriminating ADHD
symptoms between those children with OLD versus both
OLD and ADHD. Findings suggest that an instrument
which includes objective measurement of subtle move-
ment could be a useful tool in the assessment of children
with and OLD and those with OLD and comorbid
ADHD.
While research suggests that stimulant medication im-
proves attention and body control, the role of medication
on attention and movement in children with OLD and
ADHD has not been explored in terms of 1) does medica-
tion improve attention and/or movement, and 2) does
medication improve attention and/or movement over
time. By testing a subsample of the children who were on
prescribed medication on separate days both on and off of
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later, individuals with both OLD and ADHD were found
to have better body control (all six movement variables)
when on stimulant medication and that the findings were
stable over time. The current study’s findings were con-
sistent with other studies identifying stimulant medication
to improve body control in children with ADHD
[14,15,37]. Equally important, results indicated that stimu-
lant medication did improve overall attention perform-
ance in those with comorbid OLD and ADHD disorders.
Specifically those children with both OLD and ADHD had
significantly better accuracy, fewer omission errors, better
response consistency, faster responding, and less variabil-
ity when tested on medication compared to their perform-
ance off medication. The current study did not find
differences between on versus off medication for commis-
sion errors (i.e., inhibition in responding to non-targets).
The current study also investigated the role of medica-
tion (on medication versus off medication) on attention
state in OLD and ADHD children using the Quotient®
ADHD System. It was expected that children tested on
medication would have fewer attention shifts and more
on task, less distracted, less impulsive, less random, less
minimal, and less contrary attending. Results indicated
that medication improved remaining on task (i.e., mostly
responding accurately), being less distracted (i.e., less
time hitting some targets and some non-targets), and
minimal response patterns (i.e., less time missing most
targets and non-targets). However, there were no signifi-
cant differences in on versus off medication performance
on attention shifts, impulsive responding, random
responding, and contrary attention states.
Methodological limitation and future research
Despite significant findings for differentiating diagnostic
categories and effects of stimulant medication as identified
by the Quotient® ADHD System, some limitations for the
current study are considered. As noted earlier, the small
sample size may not have detected important group, time,
and interaction differences. Power analyses for the attention
measures suggested that a fairly large number of subjects
would be required (typically > 200 per group). Nonetheless,
for the movement measures it is important to note that a
number of significant differences had large effects sizes sup-
porting that the differences were large enough to be de-
tected with small sample sizes which supports that the
findings are nonetheless robust. Likewise, the findings were
corroborated when replicated a year later.
A second limitation suggests caution in generalizing
findings. Children in the study represented a sample of
opportunity selected from a pool of participants enrolled
in a specially developed language intervention program
[27] at a large private school for children for learning dif-
ferences. Nonetheless, the importance is the uniqueopportunity to study what would be considered a fairly
large homogenous sample of children with well identified
oral/language differences involved in a structured learning
intervention program, a subgroup which also had comor-
bid ADHD. And finally, secondary analyses related to the
effects of medication merit caution given the limitations
inherent in the design.
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